Elevance Health, Inc. Revenue & Financials

The financial narrative of Elevance Health over the past five years is a complex tapestry of massive top-line scale, margin volatility driven by medical utilization trends, and the heavy capital investment required to execute its vertical integration strategy. Following the pandemic-induced suppression of medical utilization, which generated windfall underwriting margins in 2020 and 2021, the company entered a period of significant medical cost normalization and inflation. In fiscal year 2022, Elevance reported robust top-line growth, reaching $156.5 billion in total revenue, driven by strong membership growth in its Medicaid and Medicare Advantage books, alongside favorable pricing in the commercial segment. However, as medical utilization began to rebound in late 2022 and throughout 2023, particularly in inpatient admissions, outpatient surgeries, and high-cost specialty pharmacy, the company faced severe pressure on its Medical Loss Ratio. This utilization rebound compressed operating margins, forcing the company to deploy significant pricing actions for the 2024 plan year to restore actuarial balance. In fiscal year 2023, revenue grew to $156.6 billion, reflecting the company's massive scale, but net income faced downward pressure as the medical cost trends outpaced premium growth in certain quarters, highlighting the inherent volatility of the managed care business model. Moving into fiscal year 2024, Elevance demonstrated remarkable financial resilience and strategic execution, reporting a significant acceleration in top-line growth to $159.3 billion. This growth was fueled by the continued expansion of its Carelon Businesses segment, which provided higher-margin revenue and helped offset the medical cost pressures in the Health Benefits segment. The company successfully implemented aggressive premium increases and optimized its provider networks, gradually stabilizing the MLR and restoring profitability to its target ranges. The integration of the WellCare acquisition, completed in 2020, has now fully matured, providing a highly efficient, low-cost administrative infrastructure for the Medicaid book that generates substantial free cash flow. The company's balance sheet remains fortified by a conservative leverage profile and robust cash flow generation, providing the financial flexibility to continue investing heavily in the build-out of Carelon, funding strategic technology initiatives, and returning capital to shareholders through consistent dividend payments and aggressive share repurchase programs. The financial story of Elevance Health is one of a company that has successfully navigated the post-pandemic medical cost shock, utilizing its massive scale and diversified membership base to absorb the volatility, while simultaneously executing a capital-intensive pivot toward vertical integration that is expected to drive long-term margin expansion and sustainable, profitable growth.